November 17, 2020 -- Moderna said that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use has initiated a rolling review of the firm's messenger RNA (mRNA)-1273 COVID-19 vaccine candidate. The company has also inked an agreement to supply the vaccine to the U.K. government.
As it continues its ongoing dialogue with the EMA, Moderna said it's also scaling up global manufacturing with its strategic partners Lonza of Switzerland and ROVI of Spain in order to be able to deliver approximately 500 million doses per year and possibly up to 1 billion doses per year beginning in 2021.
In a related development, Moderna has also signed a deal to supply mRNA-1273 to the U.K. government. Supply would begin in March 2021 if the vaccine candidate is approved by the U.K. regulatory authorities. The Medicines and Healthcare products Regulatory Agency began its rolling review process of mRNA-1273 on October 27, Moderna said.